Abasaglar biosimilar to Lantus (insulin glargine) is launched in UK and Germany to treat diabetes- Boehringer + Eli Lilly
Boehringer Ingelheim/ Eli Lilly’s biosimilar Abasaglar (previously Abasria) was launched in the UK and Germany at the end of August 2015 for the treatment of diabetes. In the UK the price of the biosimilar is at a 15% discount to its originator drug, Lantus (insulin glargine).The biosimilar has also been launched in Lithuania, Czech and Slovak Republics and Japan. Further introductions are conditional on Lantus patent expiry dates in individual countries.A possible launch in the US is planned for 2016 but is subject to ongoing patent litigation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.